Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

Addgene
HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase.
Chakraborty AA, Nakamura E, Qi J, Creech A, Jaffe JD, Paulk J, Novak JS, Nagulapalli K, McBrayer SK, Cowley GS, Pineda J, Song J, Wang YE, Carr SA, Root DE, Signoretti S, Bradner JE, Kaelin WG Jr
Sci Transl Med. 2017 Jul 12;9(398):eaal5272. doi: 10.1126/scitranslmed.aal5272. PubMed Article

Plasmids from Article

ID Plasmid Purpose
203582pLX304-EZH1-Y727FExpresses V5-tagged mutant version of EZH1 partially resistant to JQ-EZ-05 in mammalian cells.
203585pLX304-EZH1-D745NExpresses V5-tagged mutant version of EZH1 partially resistant to JQ-EZ-05 in mammalian cells.
203586pLX304-EZH1-dPSETExpresses V5-tagged mutant version of EZH1 with deletion of aa 744-747 and partially resistant to JQ-EZ-05 in mammalian cells.

Antibodies from Article